Ukwelashwa Okuphindaphindiwe Komdlavuza Wamaphaphu 2026: Ukuphumelela Okusha Nemihlahlandlela Yakamuva 

Ukwelashwa okuphindaphindiwe komdlavuza wamaphaphu ngo-2026 kugxile kumasu omuntu siqu kusetshenziswa imihlahlandlela yakamuva ye-NCCN, ukuhlolwa kwe-biomarker okuthuthukisiwe, kanye nokwelashwa okunoveli okufana nama-antibody-drug conjugates (ADCs) kanye namasosha omzimba acaciswe kabili. Ezigulini ezibhekene nokubuya kwesifo, izinketho manje zifaka ukuphonselwa inselelo kabusha ngama-ejenti angaphambilini, ukushintshela ekwelashweni okuhlosiwe okusekelwe ezindleleni zokumelana, noma ukubhalisa ezivivinyweni zomtholampilo zama-immunotherapies asafufusa.

Ukuqonda Umdlavuza Wamaphaphu Ophindaphindiwe ngo-2026

Ukuphindaphinda komdlavuza wamaphaphu kwenzeka lapho isifo sibuya ngemva kokwelashwa kokuqala, kungaba endaweni, esifundeni, noma kude. Ngo-2026, indlela yoku ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe ishintshe kakhulu isuka kumodeli yosayizi owodwa iye kumithi enembayo eqhutshwa ukuphrofayela yamangqamuzana.

Incazelo yokuphindaphinda incike esikhathini esidlulile kusukela ekwelapheni okuyisisekelo. Ukuvela kwangaphambi kwesikhathi kuvame ukuphakamisa isifo esingazweli, kuyilapho ukuvela sekwephuzile kungase kubonise isimila esisha esiyinhloko noma amaseli alele aphinde asebenze. Izivumelwano zamanje zigcizelela ukuhlukanisa phakathi kwalezi zimo ukuze kuqondiswe ukukhethwa kokwelashwa ngempumelelo.

Amathuluzi esimanje okuxilonga manje avumela odokotela ukuthi babone izifo ezincane ezisalela ngokushesha kunangaphambili. Leli windi lokutholwa kusenesikhathi linikeza ithuba elibalulekile lokungenelela ngaphambi kokuba umthwalo we-tumor ungalawuleki, okwenza ngcono kakhulu imiphumela yesiguli.

Izinhlobo Zokuphindaphinda Nemiphumela Yazo

Ukuphinda kuhlukaniswe ngezinhlobo ezintathu eziyinhloko: indawo, isifunda, nekude. Ukuphindaphinda kwendawo kwenzeka endaweni yokuqala yesimila, kanti ukuphinda kwesifunda kubandakanya ama-lymph node aseduze. Ukuvela okukude, noma i-metastasis, kuthinta izitho ezifana nobuchopho, amathambo, noma isibindi.

• Ukuphinda Kwendawo: Imvamisa iphathwa ngenhloso yokwelapha kusetshenziswa ukuhlinzwa noma ngemisebe uma ingazange iphele amandla ngaphambilini.
• Ukuphinda kwesifunda: Kungase kudinge inhlanganisela yokwelashwa kwesistimu kanye nokwelashwa kwendawo.
• Ukuphindaphinda Okukude: Ivamise ukuphathwa ngemithi yokwelapha ehlelekile, egxile ekwandiseni isikhathi sokuphila nokugcina izinga lempilo.

Ukuqonda iphethini yokuphindaphinda kubalulekile. Isibonelo, isifo se-oligometastatic (ukusabalala okulinganiselwe) sisengavunyelwa ekwelashweni kwasendaweni okunolaka njengokwelashwa ngemisebe ye-stereotactic body (SBRT), enikeza ukulawula okungaba khona isikhathi eside.

Imihlahlandlela yakamuva ye-NCCN Yomdlavuza Wamaphaphu Ongasiwo Owomncane Weseli

I-2026 NCCN Clinical Practice Guidelines for Non-Small Cell Lung Cancer (NSCLC) yethula izibuyekezo ezibalulekile ezihambisana nesifo esiphindelelayo. Ushintsho olukhulu ukwamukelwa kwendawo yonke yohlelo lwesiteji lwe-AJCC 9th Edition TNM, okuqinisekisa ukuhlukaniswa okunembayo nokuhlola okubikezelwayo.

Ezimweni eziqhubekayo, imihlahlandlela igcizelela isidingo sokuphinda ukuhlolwa kwe-biomarker. Amathumba angavela, athole ukuguqulwa okusha okwenza ukwelapha kwangaphambilini kungasebenzi. Ngakho-ke, i-re-biopsy noma i-liquid biopsy manje isiwumkhuba ojwayelekile wokuhlonza okuqondiwe okungenziwa.

Izindlela zokuxilonga nazo zenziwe zathuthukiswa. Iziguli ezisengcupheni enkulu ziyelulekwa ukuthi zigadwe ngezithombe njalo ezinyangeni eziyi-12 ukuze zibone ukuthuthuka okuncane kusenesikhathi. Lokhu kuqapha okusebenzayo kusiza ekungeneleleni okufika ngesikhathi, kuvimbele ukusabalala okusabalele.

Izimiso Zokwelapha Eziqondiswe Nge-Biomarker

Imihlahlandlela yango-2026 igqamisa izimiso ezithile zokwelashwa okuqondiswe ku-biomarker kuzilungiselelo ezithuthukisiwe noma ze-metastatic. Isibuyekezo esisodwa esiphawulekayo sibandakanya ukuphathwa kwe-Amivantamab. Ukwakheka kwe-subcutaneous ne-hyaluronidase manje sekuyindlela eyamukelwe esikhundleni sokulethwa ngomthambo, okunikeza lula ngaphandle kokuphazamisa ukusebenza kahle.

Lolu shintsho lubonisa ukuthambekela okubanzi ekunakekelweni kwesiguli, ukunciphisa ukuvakashelwa ezibhedlela kanye nezikhathi zokumnika. Kodwa-ke, imiyalo yokudosa iyahluka phakathi kwezithako, ezidinga ukunakwa ngokucophelela kubahlinzeki bezempilo ukuze kuqinisekiswe ukuphepha nokusebenza ngempumelelo.

Ngaphezu kwalokho, imihlahlandlela incoma ukugcwaliseka kwephrofayili ye-genomic yazo zonke iziguli ezinesifo esiphindelelayo, kungakhathaliseki umlando wokuhlola wangaphambilini. Lokhu kuqinisekisa ukuthi akukho okuhlosiwe okuvelayo okugejiwe, njengokuguqulwa kwe-HER2 noma okuhlukile kwe-KRAS G12C, okunezinketho ezintsha zokwelapha ezitholakalayo.

Izindlela Zokwelapha Eziphumelelayo Zomdlavuza Wamaphaphu Ophindaphindiwe

Indawo ye ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe iye yashintshwa izindlela zokwelapha ezimbalwa ezethulwe noma zaqinisekiswa ngasekuqaleni kuka-2026. Lezi zindlela ezintsha zinikeza ithemba ezigulini ezithuthuke emigqeni yokwelapha evamile.

Ama-antibody-drug conjugates (ADCs) avele njengesisekelo ekwelapheni amacala aphikisayo. Ama-ejenti aqondise ku-TROP2 kanye ne-HER2 abonise ukusebenza kahle okumangalisayo ezigulini ezinokuguquguquka kwe-EGFR eziye zaqeda i-tyrosine kinase inhibitors (TKIs).

Ukwengeza, amasosha omzimba angama-bispecific athola amandla. Lawa ma-molecule ahlanganisa izinhloso ezimbili ezihlukene ngasikhathi sinye, athuthukisa ukusabela kokuzivikela komzimba futhi avimbe izindlela eziningi zokukhula. Idatha yakamuva iphakamisa ukuthi bangakwazi ukunqoba izindlela zokumelana ezikhawulela ukwelashwa kwe-ejenti eyodwa.

Iqhaza lama-Antibody-Drug Conjugates (ADCs)

Ama-ADC ahlanganisa i-monoclonal antibody ne-cytotoxic payload, ehambisa ukwelashwa ngamakhemikhali ngokuqondile kumaseli omdlavuza kuyilapho esindisa izicubu ezinempilo. Ngo-2026, izidakamizwa ezifana ne-Trastuzumab Deruxtecan kanye ne-Datopotamab Deruxtecan zibalulekile ku-NSCLC ephindayo.

Izivivinyo zemitholampilo, njenge-OptiTROP-Lung03, zibonise ukuthi ama-ADC angathuthukisa kakhulu ukusinda kukonke uma kuqhathaniswa nokwelashwa ngamakhemikhali okungokwesiko. Isibonelo, iziguli ezalashwa nge-EGFR-mutant NSCLC zithole ukuphila okumaphakathi kwezinyanga ezingama-20 ngemithi ethile ye-ADC.

Indlela yokusebenza ihlanganisa ukubophezela kuma-antigen angaphezulu agcizelelwe ngokweqile kumaseli wesimila, ukufakwa ngaphakathi, kanye nokukhululwa komthwalo okhokhelwayo onobuthi. Le ndlela eqondisiwe inciphisa imiphumela engemihle yesistimu, iyenze ifanelekele iziguli ezibuthaka ezingakwazi ukubekezelela imishanguzo eqinile yokwelapha ngamakhemikhali.

Ama-Antibodies Anezici Ezimbaxambili kanye ne-Novel Immunotherapies

Amasosha omzimba acaciswe kabili amelela omunye umngcele. I-Pumitamig, i-PD-L1 kanye ne-VEGF-A ye-bispecific antibody, ibonise imiphumela ethembisayo ezivivinyweni zeSigaba 1b/2a zomugqa wokuqala wokwelashwa kwe-PD-L1 positive NSCLC. Ikhono layo lokuvimba izindawo zokuhlola amasosha omzimba kanye nokuvimbela i-angiogenesis kanyekanye kudala indawo enamandla yokulwa nesimila.

Ngaphezu kwalokho, ama-immunotherapies amasha ayahlolwa ezigulini ezithuthuka kuma-PD-(L)1 inhibitors akhona. I-Gotistobart, njengamanje ekulingweni kweSigaba 3, iqhathanisa kahle ne-docetaxel ku-NSCLC ye-metastatic squamous, enikeza umugqa omusha wokuzivikela kulabo abanezinketho ezilinganiselwe.

Lawa ma-ejenti asebenza ngokubandakanya ama-T-cell ngempumelelo kakhulu noma aqondise ezinye izindlela zokuzivikela ezifweni. Ukuhlukahluka kwezinqubo kuqinisekisa ukuthi ngisho noma indlela eyodwa ivinjwe yi-tumor, ezinye zihlala zifinyeleleka ukuze kungenelele ukwelashwa.

Amasu e-EGFR-Mutant Recurrent Lung Cancer

Umdlavuza wamaphaphu oguquguqukayo we-EGFR uletha izinselelo eziyingqayizivele lapho uphindaphinda, ikakhulukazi mayelana nezindlela zokumelana. Ingqungquthela ye-ELCC ka-2026 yaqokomisa idatha eyisisekelo ekulawuleni lawa macala ayinkimbinkimbi, igcizelela amasu okuhlanganisa kanye nama-ejenti esizukulwane esilandelayo.

Ucwaningo lwe-TOP luveze ukuthi ukuhlanganisa i-Osimertinib ne-chemotherapy kuthuthukisa kakhulu ukusinda kwe-progression-free survival (PFS) ezigulini ezinokuguqulwa okuhlangene kwe-TP53. Leli qembu elincane ngokuvamile linemiphumela emibi kakhulu nge-TKI monotherapy, okwenza inhlanganisela iguqule umdlalo.

Imiphumela ibonise i-PFS emaphakathi yezinyanga ezingama-34.0 yeqembu elihlanganisiwe uma liqhathaniswa nezinyanga eziyi-15.6 ku-Osimertinib iyodwa. Le nzuzo enkulu igcizelela ukubaluleka kokuhlonza amaphrofayili ofuzo asengozini enkulu kusenesikhathi kanye nokuhlanganisa ukwelashwa ngendlela efanele.

Imithi Yokwelapha Ehlanganisiwe kanye Nokuhlanganiswa Kwendawo

Ngaphandle kwezinhlanganisela ze-systemic, ukwelashwa kokuhlanganiswa kwendawo (LCT) kubonakala kuwusizo. Ucwaningo lwe-NorthStar lubonise ukuthi ukwengeza i-LCT (ukuhlinzwa noma imisebe) ku-Osimertinib kuthuthukisa i-PFS ku-metastatic EGFR-mutant NSCLC.

Iziguli ezithola i-LCT zithole i-PFS emaphakathi yezinyanga ze-25.4 uma kuqhathaniswa nezinyanga ze-17.5 nge-Osimertinib kuphela. Ucwaningo lubonisa ukuthi ukusula izifo ezisele ku-thorax kungabambezela ukuqhubeka kwesistimu, uma nje ama-metastases akude elawulwa.

Izinkomba ezibalulekile zenzuzo ye-LCT zifaka phakathi ukucaciswa kwe-pleural effusions kanye nama-lymph nodes aphakathi ngemva kokwelashwa kokungeniswa. Lokhu kuhlukaniswa kusiza odokotela ukuthi bakhethe abantu abangase bahlomule endleleni ye-multimodal enolaka.

Ukuphatha Resistance Mechanisms

Ukumelana nama-EGFR TKIs kuvame ukuvela ngokuguqulwa kwesibili okufana ne-C797S noma ukuguqulwa kwe-phenotypic okufana nomdlavuza omncane wamaphaphu (SCLC). Ukubhekana nalokhu kudinga amasu ahlukene.

• Ukuguqulwa kwe-C797S: Ama-TKI amasha esizukulwane sesine asathuthuka ukuze aqondise lokhu kuguqulwa kokumelana okuqondile, okubonisa isithembiso sangaphambi kwesikhathi kuzifundo zomtholampilo zangaphambi komtholampilo kanye nezasekuqaleni.
• Ukuguqulwa kwe-SCLC: Lapho i-NSCLC iguqulela ku-SCLC, ukushintshela ku-platinum-etoposide chemotherapy kuyindinganiso yokunakekelwa, ngokuvamile enikeza izimpendulo ezisheshayo.
• I-MET Amplification: Ukwelapha okuhlanganisiwe nama-MET inhibitors kanye nama-EGFR TKIs kusebenza kahle ezigulini ezithuthukisa i-MET amplification njengendlela yokumelana.

Ukuqapha njalo nge-liquid biopsy kuvumela ukutholwa kwalezi zinguquko ngesikhathi sangempela, okuvumela ukuzivumelanisa nezimo ngokushesha kohlelo lokwelapha ukuze kugcinwe ukulawulwa kwezifo.

Izindlela Zokwelashwa Zokuphindeka Komdlavuza Wengqamuzana Encane

I-Small Cell Lung Cancer (SCLC) yaziwa ngemvelo yayo enolaka kanye nezinga eliphezulu lokuphindaphinda. Imihlahlandlela ka-2026 ye-NCCN ye-SCLC ihlinzeka ngezincomo ezibuyekeziwe zokulawula izifo ezibuye zibe khona, ezigxile ekwandiseni izindlela zokwelapha zomugqa wesibili nezilandelayo.

Ezigulini eziphindela emuva ezinyangeni ezingaphezu kweziyisithupha ngemuva kokwelashwa kokuqala, ukuphinda kuphonselwe inselelo ngohlelo lwangempela olusekelwe kwiplatinamu kuvame ukucatshangelwa. Kodwa-ke, kulabo ababuyela emuva ngokushesha, ama-agent ahlukile ayadingeka ukuze kugwenywe ukumelana.

Ukuhlanganiswa kwe-immunotherapy kusilungiselelo somugqa wokuqala kuguqule isimo semigqa elandelayo. Iziguli ezithuthuka ngemva kwe-chemo-immunotherapy zidinga izindlela ezintsha, ezihlanganisa ama-chemotherapeutic agents amasha kanye nemithi yokwelapha ehlosiwe ngaphansi kophenyo.

Izinketho Zomugqa Wesibili kanye Nangaphandle

I-Lurbinectedin izitholele yona njengomdlali oyinhloko ku-SCLC eqhubekayo, enikeza iphrofayela evumayo yobuthi namazinga okuphendula aphusile. Kuwusizo ikakhulukazi ezigulini ezingakwazi ukubekezelela okunye ukwelashwa ngeplatinamu.

I-Topotecan isalokhu iyinketho evamile, etholakala kuzo zombili izinhlobo zomlomo kanye ne-intravenous. Nakuba kusebenza kahle, ukusetshenziswa kwayo ngezinye izikhathi kukhawulwa yi-myelosuppression, edinga ukuphathwa ngokucophelela komthamo nokunakekelwa okusekelayo.

Izivivinyo zemitholampilo ziya ngokuya zibaluleke kakhulu ku-SCLC ngenxa yokuqina okulinganiselwe kwemithi yokwelapha yomugqa wesibili. Izidakamizwa eziphenyayo eziqondise ku-DLL3, njengezihlanganisi ze-T-cell bispecific, zibonisa imiphumela yokuqala ethokozisayo futhi ingase ibe ingxenye ye-armamentarium evamile.

Iqhaza Le-Prophylactic Cranial Irradiation and Surveillance

Ama-metastase obuchopho ayindawo evamile yokuphindaphinda ku-SCLC. Indima ye-prophylactic cranial irradiation (PCI) ibuyekezwa kabusha enkathini yokubhekwa njalo kwe-MRI.

Amathrendi amanje athanda ukuqapha okusondele kwe-MRI ngaphezu kwe-PCI evamile yeziguli ezikhethiwe ukugwema ukwehla kwe-neurocognitive. Kodwa-ke, kulabo abanesifo esibanzi noma ukungahambisani kahle nokulandelwa, i-PCI ihlala iyindlela ephumelelayo yokuvimbela ukuphindeka kwesistimu yezinzwa ephakathi.

Ukutholwa kusenesikhathi kwama-metastases obuchopho ngokuthwebula okuvamile kuvumela ukungenelela okufika ngesikhathi ngokuhlinzwa kwe-stereotactic radiosurgery (SRS), ukulondoloza ukusebenza kwezinzwa nokwandisa ukuphila ngaphandle kwemiphumela engemihle ebanzi yemisebe yobuchopho obuphelele.

Ukuhlaziywa Okuqhathaniswayo Kwezindlela Zokwelapha

Ukukhetha ilungelo ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe kuhlanganisa ukulinganisa izici ezihlukahlukene ezihlanganisa ukusebenza kahle, ubuthi, kanye nokuthandwa yisiguli. Ithebula elilandelayo liqhathanisa izindlela zokwelapha ezibalulekile ezitholakala ngo-2026.

Lesi siqhathaniso sigqamisa ukuthi ayikho indlela eyodwa elingana konke. Ukukhetha kuncike kakhulu ekwakhekeni kwamangqamuzana ethumba eliphindaphindayo kanye nomlando wokwelashwa wangaphambili wesiguli.

Izinyathelo Ezisebenzayo Zeziguli Nabanakekeli

Ukuzulazula ekuxilongweni komdlavuza wamaphaphu ophindelelayo kungaba nzima. Ukuthatha izinyathelo ezihlelekile kungasiza iziguli nabanakekeli balawule isimo ngempumelelo futhi benze izinqumo ezinolwazi mayelana ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe.

• Isinyathelo 1: Qinisekisa Ukuphinda: Qinisekisa ukuxilongwa okunembile ngokusebenzisa izithombe ezithuthukisiwe (PET/CT, MRI) kanye ne-biopsy. Iphrofayili yamangqamuzana ibalulekile ukuze kukhonjwe okuhlosiwe okusha.
• Isinyathelo sesi-2: Buyekeza Umlando Wezokwelapha: Hlanganisa irekhodi elinemininingwane yokwelashwa kwangaphambilini, izimpendulo, nemiphumela engemihle. Lokhu kusiza ama-oncologists ukuthi ahlele umugqa olandelayo wokwelapha.
• Isinyathelo sesi-3: Funa Imibono Yesibili: Xhumana nochwepheshe ezikhungweni zomdlavuza ezibanzi. Ukufinyelela ezivivinyweni zemitholampilo kanye namathimba emikhakha eminingi kungavula izinketho ezintsha.
• Isinyathelo sesi-4: Xoxa Ngezinjongo Zokunakekela: Iba nezingxoxo ezivulekile mayelana nemigomo yokwelashwa, noma ngabe ekwelapheni noma ekudambiseni. Ukuqondanisa okulindelwe kuqinisekisa ukuthi indlela ekhethiwe ifana namanani esiguli.
• Isinyathelo sesi-5: Gada futhi Uguqule: Hlala uqaphile ngama-aphoyintimenti okulandelela nokuskena. Zilungiselele ukulungisa uhlelo lokwelapha njengoba isifo sishintsha noma kuvela idatha entsha.

Ukuzibandakanya ngenkuthalo ohlelweni lokunakekelwa kunika iziguli amandla futhi kuvame ukuholela emiphumeleni engcono. Amaqembu okusekela kanye nezinhlangano ezimelela isiguli zinganikeza izinsiza ezibalulekile nokusekelwa ngokomzwelo.

Izinzuzo Nezimbi Zendlela Enolaka vs. I-Palliative Approaches

Ukunquma phakathi kokwelashwa okunonya nokunakekelwa kwe-palliative kuyisinyathelo esibalulekile. Indlela ngayinye inezinzuzo ezihlukile kanye nezithiyo okufanele zicatshangelwe ngokucophelela.

• Indlela Enamandla:
  • Okuhle: Amathuba okusinda isikhathi eside, ithuba lokuxolelwa ezimweni ze-oligometastatic, ukufinyelela ekwelashweni okuphambili.
  • Ububi: Ingozi ephezulu yemiphumela emibi kakhulu, ukuvakashelwa njalo esibhedlela, umthelela ongaba khona ezingeni lempilo.
• Indlela ye-Palliative:
  • Okuhle: Gxila ekulawulweni kwezimpawu, izinga lempilo elithuthukisiwe, ubuthi obuncane obuhlobene nokwelashwa.
  • Ububi: Umthelela olinganiselwe ekukhuleni kwesimila, isikhathi esingaba sifushane sokusinda, inselele yengqondo yokwamukela imikhawulo.

Isinqumo kufanele sibe namandla, sibuyekezwe njalo njengoba isithombe somtholampilo sishintsha. Iziguli eziningi zithola indawo emaphakathi, zisebenzisa ukwelashwa okusebenzayo kuyilapho zibeka phambili izinga lempilo ngezinsizakalo zokunakekela ezididiyelwe zokuthopha.

Izikhombisi-ndlela zesikhathi esizayo kanye nocwaningo olusafufusa

Inkambu ye ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe ithuthuka ngokushesha, kunezifundo eziningi eziqhubekayo zokubhekana nezidingo ezingahlangatshezwana nazo. Izikhombisi-ndlela zesikhathi esizayo zikhomba ekwelashweni komuntu siqu nakakhulu futhi okuncane kakhulu.

Ucwaningo lwama-EGFR inhibitors esizukulwane sesine luhlose ukunqoba ukumelana ne-C797S, isithiyo esikhulu ku-EGFR-mutant NSCLC. Izivivinyo zesigaba sasekuqaleni ziphakamisa ukuthi lawa ma-ejenti angabuyisela ukuzwela kumathumba ayekade ephikisa.

Ukwengeza, ukuhlolwa kwemithi yokugomela i-neoantigen kanye nemigomo yomuntu siqu yomdlavuza kunesithembiso esikhulu. Ngokuqeqesha amasosha omzimba ukuthi abone izimpawu ezihlukile zesimila, lezi zindlela zokwelapha zinganikeza ukuzivikela okuhlala isikhathi eside ngokumelene nokuphindeka.

Umthelela Wokuhlakanipha Kokwenziwa kanye Nezempilo Yedijithali

I-Artificial intelligence (AI) isiqala ukudlala indima yokuguqula ekulawulweni komdlavuza wamaphaphu. Ama-algorithms e-AI angahlaziya amanani amaningi ezithombe kanye nedatha ye-genomic ukuze abikezele ubungozi bokuphinda futhi aphakamise izindlela zokwelashwa ezilungile.

Amathuluzi ezempilo edijithali anika amandla ukuqapha okukude kweziguli, ukulandelela izimpawu nokubambelela emithini ngesikhathi sangempela. Le luphu yempendulo eqhubekayo ivumela ukungenelela okusheshayo nokulungiswa kokunakekelwa komuntu siqu.

Ngaphezu kwalokho, izinkundla eziqhutshwa yi-AI zenza kube lula ukufaniswa kweziguli ezivivinyweni zomtholampilo ezifanele, kusheshisa ukubhaliswa kanye nokuqinisekisa ukuthi abantu abafanelekile abaphuthelwa amathuba okungenzeka andise impilo.

Isiphetho

Indawo ye ukwelashwa komdlavuza wamaphaphu okuphindaphindiwe ngo-2026 ibonakala ngokunemba okungakaze kubonwe kanye nokuqamba okusha. Kusukela ekwamukelwa kohlelo lwesiteji lwe-AJCC 9th Edition kuya ekusetshenzisweni kwama-ADC asethuthukile kanye namasosha omzimba ahlukene kabili, iziguli zinezinketho eziningi kunangaphambili.

Okuthathwayo okubalulekile kufaka phakathi ukubaluleka okubalulekile kokuphinda ukuhlolwa kwe-biomarker, ukubaluleka kwamasu okuhlanganisa amaqembu asengozini enkulu, kanye nendima ekhulayo yokuhlanganiswa kwendawo esifweni se-oligometastatic. Njengoba ucwaningo luqhubeka lwembuleka, ikusasa lithembisa izindlela zokwelapha eziphumelela nakakhulu neziklanyelwe.

Iziguli nabanakekeli bayakhuthazwa ukuthi bahlale benolwazi, bazibandakanye namathimba abo okunakekelwa kwezempilo, futhi bacabangele izivivinyo zomtholampilo njengenketho esebenzayo. Ngendlela efanele, umdlavuza wamaphaphu ophindelelayo ungalawuleka ngempumelelo, unwebe ukusinda nokugcina izinga lempilo.